Upcoming Trial Readouts
| Company | Date | Drug | Description | |
|---|---|---|---|---|
Ionis Pharmaceuticals, Inc. (IONS) | 2025- | Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 | source | |
BridgeBio Pharma, Inc. (BBIO) | 2024-08-30T00:00:00Z | Additional data from Phase 3 ATTRibute-CM and open-label extension study of acoramidis in ATTR-CM presented at ESC 2024 | source | |
Alnylam Pharmaceuticals, Inc. (ALNY) | 2024-08-30TAPPROX | source | ||
Merck & Co., Inc. (MRK) | 2024-09-01T00:00:00Z | Phase 3 Trial Initiation for Bomedemstat | source | |
Vaxcyte, Inc. (PCVX) | 2024-09-03T08:00:00Z | Topline results from Phase 1/2 study of VAX-31 | source | |
Pfizer Inc. (PFE) | 2024-09-14T00:00:00Z | Presentation of longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial | source | |
Pfizer Inc. (PFE) | 2024-09-14TAPPROX | Phase 2 study results presentation at ESMO 2024 Congress | source | |
Johnson & Johnson (JNJ) | 2024-09-15T00:00:00Z | TAR-200 +/- Cetrelimab and Cetrelimab Alone in Patients With Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Updated Results From SunRISe-1. ESMO 2024 | source | |
Johnson & Johnson (JNJ) | 2024-09-16T00:00:00Z | Interim analysis of the SunRISe-4 study presented at ESMO 2024 Congress | source | |
Rocket Pharmaceuticals, Inc. (RCKT) | 2024-09-17T00:00:00Z | RP-A501 Phase 2 Pivotal Trial Enrollment Completed | source | |
Sanofi (SNY) | 2024-09-20T00:00:00Z | Presentation of HERCULES and GEMINI 1 and 2 study results at ECTRIMS medical meeting | source | |
IDEAYA Biosciences, Inc. (IDYA) | 2024-09-23T08:00:00Z | Interim Phase 2 data for darovasertib and regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM) | source | |
Kronos Bio, Inc. (KRON) | 2024-09-23T08:55:00Z | New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance | source | |
Alkermes plc (ALKS) | 2024-09-24T00:00:00Z | Presentation of clinical data from phase 1b study of ALKS 2680 in patients with narcolepsy type 2 and idiopathic hypersomnia at Sleep Europe 2024 | source | |
Arcutis Biotherapeutics, Inc. (ARQT) | 2024-09-25T00:00:00Z | Pooled subgroup analysis results from Phase 3 INTEGUMENT-1 and -2 trials | source | |
Eli Lilly and Company (LLY) | 2024-09-25T00:00:00Z | Long-term results from the ADjoin long-term extension study to be presented at the European Academy of Dermatology and Venereology (EADV) Congress | source | |
Johnson & Johnson (JNJ) | 2024-09-27T00:00:00Z | Talquetamab + daratumab + pomalidomide in patients with relapsed/refractory multiple myeloma: Results from the phase 1b TRIMM-2 study. IMS 2024. | source | |
Cytokinetics, Incorporated (CYTK) | 2024-09-27T00:00:00Z | Additional data from SEQUOIA-HCM trial of aficamten | source | |
Johnson & Johnson (JNJ) | 2024-09-27T00:00:00Z | Results of the Phase 3 CEPHEUS study presented at the 2024 International Myeloma Society Annual Meeting | source | |
Johnson & Johnson (JNJ) | 2024-09-27T00:00:00Z | RedirecTT-1 study Phase 1b results presentation at IMS | source | |
Zevra Therapeutics, Inc. (ZVRA) | 2024-09-27T08:20:00Z | Safety and Efficacy of KP1077 in a Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Patients with Idiopathic Hypersomnia | source | |
scPharmaceuticals Inc. (SCPH) | 2024-09-30T00:00:00Z | Topline data expected for SCP-111 (furosemide 80 mg/mL) in Q3 2024 | source | |
Ascendis Pharma A/S (ASND) | 2024-09-30T00:00:00Z | Palopegteriparatide Improves Skeletal Dynamics in Adults with Chronic Hypoparathyroidism: 3 Year Results from the Phase 2 PaTH Forward Trial (#1091) | source | |
Merck & Co., Inc. (MRK) | 2024-10-01T00:00:00Z | STRIDE-8 results presented at IDWeek | source | |
Gilead Sciences, Inc. (GILD) | 2024-10-01T00:00:00Z | NEJM published full results from the Phase 3 PURPOSE 2 trial for lenacapavir | source | |
Johnson & Johnson (JNJ) | 2024-10-02T00:00:00Z | Real-world study results of ERLEADA vs. enzalutamide in patients with metastatic castration-sensitive prostate cancer presented at ECOP | source | |
GSK plc (GSK) | 2024-10-08T00:00:00Z | Data from AReSVi-006 Phase III Trial Presentation at CHEST 2024 Annual Meeting | source | |
Viking Therapeutics, Inc. (VKTX) | 2024-10-09T00:00:00Z | Phase 1b clinical trial results presented for VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) | source | |
Eli Lilly and Company (LLY) | 2024-10-15T00:00:00Z | Presentation at United European Gastroenterology (UEG) Week | source | |
GSK plc (GSK) | 2024-10-16T00:00:00Z | New real-world evidence and implementation data presentation for Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP) at IDWeek 2024 | source | |
Vertex Pharmaceuticals Incorporated (VRTX) | 2024-10-18T00:00:00Z | Pivotal Phase 3 data presentation on suzetrigine at the annual meeting of the American Society of Anesthesiologists | source | |
Regeneron Pharmaceuticals, Inc. (REGN) | 2024-10-18T00:00:00Z | Three-year data for EYLEA HD from PHOTON trial presented at AAO | source | |
Merck & Co., Inc. (MRK) | 2024-10-19T00:00:00Z | Long-term efficacy and safety data for tulisokibart in ulcerative colitis and Crohn’s disease | source | |
Merck & Co., Inc. (MRK) | 2024-10-19T00:00:00Z | Positive Results from Phase 2b/3 Clinical Trial Presentation | source | |
IDEAYA Biosciences, Inc. (IDYA) | 2024-10-24T09:00:00Z | Additional poster presentations at the EORTC-NCI-AACR Symposium on preclinical data for the MAT2A and PARG programs | source | |
Eli Lilly and Company (LLY) | 2024-10-25T00:00:00Z | New results from the Phase 3b ADapt study to be presented at the Fall Clinical Dermatology (FCD) Conference | source | |
Eli Lilly and Company (LLY) | 2024-10-25T00:00:00Z | Results from Phase 3 studies on mirikizumab in UC and Crohn's disease at ACG Annual Meeting | source | |
IDEAYA Biosciences, Inc. (IDYA) | 2024-10-25T15:00:00Z | Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in MTAP-deletion urothelial and non-small cell lung cancer patients | source | |
Intellia Therapeutics, Inc. (NTLA) | 2024-10-26T00:00:00Z | Presentation of Phase 2 data for NTLA-2002 | source | |
Immunovant, Inc. (IMVT) | 2024-10-30T00:00:00Z | Data from the Phase 2a trial of batoclimab in Graves’ disease will be presented at the 2024 American Thyroid Association (ATA) Annual Meeting | source | |
Biogen Inc. (BIIB) | 2024-10-31T00:00:00Z | Latest findings for lecanemab-irmb presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD) | source | |
Rhythm Pharmaceuticals, Inc. (RYTM) | 2024-11-05T00:00:00Z | Five posters to be presented at ObesityWeek | source | |
Regeneron Pharmaceuticals, Inc. (REGN) | 2024-11-05T00:00:00Z | Positive data from the Phase 3 LIBERTY-CUPID Study C | source | |
Gilead Sciences, Inc. (GILD) | 2024-11-10T00:00:00Z | Full Results from PURPOSE 2 Study | source | |
Lexicon Pharmaceuticals, Inc. (LXRX) | 2024-11-11T00:00:00Z | Presentation at Kidney Week 2024 on Phase 3 SCORED Clinical Trial Analysis | source | |
Spyre Therapeutics, Inc. (SYRE) | 2024-11-12T08:00:00Z | Interim results from the Phase 1 SPY001 healthy volunteer trial | source | |
Kronos Bio, Inc. (KRON) | 2024-11-18T00:00:00Z | Preclinical data for KB-7898 will be presented at ACR Convergence 2024 | source | |
Rocket Pharmaceuticals, Inc. (RCKT) | 2024-11-18T09:45:00Z | Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy | source | |
BridgeBio Pharma, Inc. (BBIO) | 2024-11-18T10:00:00Z | Key results from the PROPEL 2 dataset presented at ESPE | source | |
Arrowhead Pharmaceuticals, Inc. (ARWR) | 2024-11-18T10:45:00Z | Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data from Subjects in an Open-Label Extension Trial (MUIR and SHASTA-2 OLE) | source | |
Mirum Pharmaceuticals, Inc. (MIRM) | 2024-11-18T13:00:00Z | Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis | source | |
Viking Therapeutics, Inc. (VKTX) | 2024-11-19T00:00:00Z | Oral Late Breaker Presentation of VK2809 Phase 2b Clinical Trial Results | source | |
ImmunityBio, Inc. (IBRX) | 2024-11-19T00:00:00Z | New data from QUILT 3.032 study | source | |
Janux Therapeutics, Inc. (JANX) | 2024-12-02T16:30:00Z | Update on Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC) | source | |
Johnson & Johnson (JNJ) | 2024-12-07T00:00:00Z | First data from the AQUILA study will be presented at the 2024 ASH Annual Meeting | source | |
Regeneron Pharmaceuticals, Inc. (REGN) | 2024-12-07T00:00:00Z | Updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial | source | |
Johnson & Johnson (JNJ) | 2024-12-09T00:00:00Z | Final analysis of Phase 3 ANDROMEDA study | source | |
GSK plc (GSK) | 2024-12-09T11:15:00Z | Results from the interim analysis of the DREAMM-7 trial | source | |
Arrowhead Pharmaceuticals, Inc. (ARWR) | 2024-12-11T00:00:00Z | Interim Clinical Data on ARO-CFB presented at the 8th Complement-Based Drug Development Summit | source | |
Eli Lilly and Company (LLY) | 2024-12-11T09:15:00Z | Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial. | source | |
Eli Lilly and Company (LLY) | 2024-12-11T12:00:00Z | Genomic profiling of ctDNA and association with efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy | source | |
Merck & Co., Inc. (MRK) | 2024-12-12T00:00:00Z | Long-term results from the OlympiA Phase 3 trial presented at the 2024 San Antonio Breast Cancer Symposium | source | |
Eli Lilly and Company (LLY) | 2024-12-12T17:30:00Z | Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment | source | |
Arvinas, Inc. (ARVN) | 2024-12-12T17:30:00Z | Vepdegestrant, a PROTAC Estrogen Receptor Degrader, Plus Abemaciclib in ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Preliminary Phase 1b Results | source | |
Pfizer Inc. (PFE) | 2024-12-12T17:30:00Z | Vepdegestrant and Abemaciclib Clinical Study Data Presentation at SABCS | source | |
Pfizer Inc. (PFE) | 2024-12-13T00:00:00Z | Results from the Phase 3 PATINA trial presentation at the San Antonio Breast Cancer Symposium | source | |
Corcept Therapeutics Incorporated (CORT) | 2024-12-31T00:00:00Z | Completion of enrollment in DAZALS trial | source | |
Nuvalent, Inc. (NUVL) | 2025-01-01T00:00:00Z | ALKOVE-1 Phase 1 Data Presentation | source | |
Nektar Therapeutics (NKTR) | 2025-01-01T00:00:00Z | Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata | source | |
BridgeBio Pharma, Inc. (BBIO) | 2025-01-01T00:00:00Z | Topline interim data from Phase 3 registrational study (FORTIFY) in individuals with LGMD2I/R9 | source | |
BridgeBio Pharma, Inc. (BBIO) | 2025-01-01T00:00:00Z | Topline interim data from Phase 3 registrational study (FORTIFY) in individuals with LGMD2I/R9 | source | |
Nuvalent, Inc. (NUVL) | 2025-01-01T00:00:00Z | ARROS-1 Phase 1 Data Presentation | source | |
Johnson & Johnson (JNJ) | 2025-01-01T00:00:00Z | Primary endpoint results of EMPOWER CAD study | source | |
BridgeBio Pharma, Inc. (BBIO) | 2025-01-01T00:00:00Z | Topline data readout from the interim analysis | source | |
Nektar Therapeutics (NKTR) | 2025-01-01T00:00:00Z | Publication of Phase 2b rezpegaldesleukin Studies Results | source | |
Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-01-01T00:00:00Z | Top-line data expected from PROGRESS study | source | |
Janux Therapeutics, Inc. (JANX) | 2025-01-01T00:00:00Z | Clinical Study Data Presentation Date Announced | source | |
IDEAYA Biosciences, Inc. (IDYA) | 2025-01-15T00:00:00Z | Phase 1 trial evaluating IDE161 in combination with KEYTRUDA in endometrial cancer patients | source | |
Eli Lilly and Company (LLY) | 2025-01-20T00:00:00Z | Positive Phase 2 results presentation for muvalaplin | source | |
Jazz Pharmaceuticals plc (JAZZ) | 2025-03-31T00:00:00Z | Top-line results from the Phase 2b clinical trial evaluating the efficacy and safety of suvecaltamide (JZP385) in adult patients with essential tremor | source | |
Vaxcyte, Inc. (PCVX) | 2025-03-31T00:00:00Z | Announcement of topline safety, tolerability, and immunogenicity data from Phase 2 study primary three-dose immunization series | source | |
Sanofi (SNY) | 2025-06-30T00:00:00Z | GEMINI 1 and 2 phase 3 study results of Tolebrutinib compared to Aubagio | source | |
Keros Therapeutics, Inc. (KROS) | 2025-06-30T00:00:00Z | Topline data from all treatment arms in the TROPOS trial | source | |
ImmunityBio, Inc. (IBRX) | 2025-06-30T00:00:00Z | Presentation of Phase 1 Study Data for CD19 t-haNK in Combination with Rituximab in NHL Patients | source | |
Ionis Pharmaceuticals, Inc. (IONS) | 2025-07-01T00:00:00Z | Topline data anticipated for zilganersen (ION373) trial in the second half of 2025. | source | |
Organon & Co. (OGN) | APPROX | source | ||
Gilead Sciences, Inc. (GILD) | APPROX | Phase 2 Clinical Study Data Presentation | source | |
Organon & Co. (OGN) | APPROX | source | ||
Madrigal Pharmaceuticals, Inc. (MDGL) | APPROX | MAESTRO-NASH OUTCOMES trial enrollment completion announcement | source | |
Lexicon Pharmaceuticals, Inc. (LXRX) | APPROX | Top-line Data Anticipated in Q1 2025 | source | |
Organon & Co. (OGN) | APPROX | Phase 3 clinical study data presentation for HLX11 | source | |
IDEAYA Biosciences, Inc. (IDYA) | APPROX | source | ||
Organon & Co. (OGN) | APPROX | source | ||
GSK plc (GSK) | APPROX | Presentation of final results from phase IIIb and phase IIb trials of Arexvy | source | |
Madrigal Pharmaceuticals, Inc. (MDGL) | APPROX | Publication of positive patient-reported outcomes data demonstrating Rezdiffra improved health-related quality of life in patients with NASH with moderate to advanced fibrosis | source | |
Lexeo Therapeutics, Inc. (LXEO) | APPROX | source | ||
Organon & Co. (OGN) | APPROX | Phase 3 comparative clinical trial results announced for Perjeta (pertuzumab) biosimilar HLX11 | source | |
Johnson & Johnson (JNJ) | APPROX | Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM) | source | |
Johnson & Johnson (JNJ) | APPROX | AURIGA, PERSEUS, and CASSIOPEIA studies data presentation at the 2024 International Myeloma Society (IMS) Annual Meeting | source | |
BridgeBio Pharma, Inc. (BBIO) | APPROX | Results from Phase 3 trial in adults with ATTR-CM presented at HFSA Annual Scientific Meeting 2024 | source | |
Johnson & Johnson (JNJ) | APPROX | First clinical outcomes announced at VIVA meeting | source | |
Intra-Cellular Therapies, Inc. (ITCI) | APPROX | Positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg | source | |
Merck & Co., Inc. (MRK) | APPROX | Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC | source | |
Alvotech (ALVO) | APPROX | Clinical Study Data Presentation Date Announced for AVT16 | source | |
Johnson & Johnson (JNJ) | APPROX | Data from nipocalimab Phase 2 DAHLIAS study presented at EULAR 2024 Congress | source | |
Alvotech (ALVO) | APPROX | Initiation of a confirmatory patient study for AVT16 | source | |
Merck & Co., Inc. (MRK) | APPROX | source | ||
Alvotech (ALVO) | APPROX | Initiation of confirmatory patient study for AVT16 | source | |
Eli Lilly and Company (LLY) | APPROX | Results from Phase 3 SURMOUNT-1 study presented at ObesityWeek 2024 | source | |
Lexicon Pharmaceuticals, Inc. (LXRX) | APPROX | SONATA-HCM Phase 3 Clinical Trial Design Details Presentation at HCMS 2024 Scientific Sessions | source | |
IDEAYA Biosciences, Inc. (IDYA) | APPROX | source | ||
Johnson & Johnson (JNJ) | APPROX | source | ||
Intellia Therapeutics, Inc. (NTLA) | APPROX | Presentation of new clinical data from Phase 1 trial of nexiguran ziclumeran in patients with transthyretin (ATTR) amyloidosis | source | |
Gilead Sciences, Inc. (GILD) | APPROX | Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch | source | |
Gilead Sciences, Inc. (GILD) | APPROX | Nearly Half of Participants with Primary Biliary Cholangitis (PBC) Achieve Alkaline Phosphatase (ALP) Normalization with Livdelzi | source | |
Gilead Sciences, Inc. (GILD) | APPROX | New Findings Demonstrate 81% of Participants Achieve Durable Biochemical Response by Month 30 with Livdelzi | source | |
Alnylam Pharmaceuticals, Inc. (ALNY) | APPROX | Presentation of Phase 1 study results of nucresiran at American Heart Association Scientific Sessions 2024 | source | |
Jazz Pharmaceuticals plc (JAZZ) | APPROX | Phase 3 first-line clinical trial HERIZON-GEA-01 | source | |
Organon & Co. (OGN) | APPROX | Comparative phase 3 clinical trial results for Perjeta (pertuzumab) biosimilar HLX11 | source | |
Johnson & Johnson (JNJ) | APPROX | Comprehensive results from ICONIC-LEAD and ICONIC-TOTAL study presentations | source | |
Biogen Inc. (BIIB) | APPROX | Phase 3 PHOENYCS GO Study Results Presentation | source | |
GSK plc (GSK) | APPROX | GLISTEN phase III trial results presentation | source | |
Merck & Co., Inc. (MRK) | APPROX | source | ||
argenx SE (ARGX) | APPROX | Decision to continue development of efgartigimod SC in ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM) | source | |
Merck & Co., Inc. (MRK) | APPROX | Phase 3 Trials Results Announcement | source | |
Johnson & Johnson (JNJ) | APPROX | source | ||
PTC Therapeutics, Inc. (PTCT) | APPROX | Topline Results of Cardinals Trial of Utreloxastat in ALS Patients | source | |
Merck & Co., Inc. (MRK) | APPROX | source | ||
GSK plc (GSK) | APPROX | source | ||
Eli Lilly and Company (LLY) | APPROX | Topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial | source | |
Merck & Co., Inc. (MRK) | APPROX | Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults | source | |
Gilead Sciences, Inc. (GILD) | APPROX | Findings from ALYCANTE Study Show Stable Long-Term Quality of Life for R/R LBCL Patients Treated with Yescarta | source | |
Johnson & Johnson (JNJ) | APPROX | Results from the MajesTEC-5 study presented at the 2024 ASH Annual Meeting | source | |
Merck & Co., Inc. (MRK) | APPROX | Phase 2 waveLINE-007 trial data presentation | source | |
Alnylam Pharmaceuticals, Inc. (ALNY) | APPROX | Detailed results of the HELIOS-B Phase 3 study of vutrisiran announced | source | |
Johnson & Johnson (JNJ) | APPROX | Results of Phase 2/3 study of nipocalimab in wAIHA | source | |
Eli Lilly and Company (LLY) | APPROX | Results from BRUIN CLL-321 study presented at 66th ASH Annual Meeting | source | |
Gilead Sciences, Inc. (GILD) | APPROX | ZUMA-5 Analysis Results Presentation | source | |
Gilead Sciences, Inc. (GILD) | APPROX | Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi) | source | |
Regeneron Pharmaceuticals, Inc. (REGN) | APPROX | Presentation of odronextamab clinical trial data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition | source | |
Alnylam Pharmaceuticals, Inc. (ALNY) | APPROX | source | ||
Alnylam Pharmaceuticals, Inc. (ALNY) | APPROX | Results from HELIOS-B Phase 3 Study Presentation at ESC Congress 2024 | source | |
Corcept Therapeutics Incorporated (CORT) | APPROX | Complete results from the DAZALS study will be presented at a medical conference next year. | source | |
Merck & Co., Inc. (MRK) | APPROX | Updates on Phase 3 Trials - KEYNOTE-867 and KEYNOTE-630 | source | |
Corcept Therapeutics Incorporated (CORT) | APPROX | source | ||
Merus N.V. (MRUS) | APPROX | Phase 2 Trial Results Presentation | source | |
Regeneron Pharmaceuticals, Inc. (REGN) | APPROX | Data presentation at an upcoming medical meeting | source | |
GSK plc (GSK) | APPROX | Full results of ANCHOR-1 and ANCHOR-2 phase III trials to be presented at a scientific congress | source | |
Johnson & Johnson (JNJ) | APPROX | Results from Phase 3 GALAXI 2 & 3 studies and Phase 3 QUASAR maintenance study of TREMFYA in CD and UC | source | |
Johnson & Johnson (JNJ) | APPROX | Findings from the Vibrance-MG study to be presented at MGFA Scientific Session | source | |
Krystal Biotech, Inc. (KRYS) | APPROX | Preliminary clinical data in post-anti-PD-1 NSCLC patients | source | |
Insmed Incorporated (INSM) | APPROX | Positive late-breaking subgroup data from the Phase 3 ASPEN study presented at CHEST 2024 Annual Meeting | source | |
Apellis Pharmaceuticals, Inc. (APLS) | APPROX | Positive results from Phase 3 VALIANT study presented at ASN Kidney Week | source | |
BridgeBio Pharma, Inc. (BBIO) | APPROX | Outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions | source | |
Nektar Therapeutics (NKTR) | APPROX | Publication of Phase 1 data for NKTR-255 in combination with CD19-22 CAR-T cell therapy | source | |
Organon & Co. (OGN) | APPROX | source | ||
Organon & Co. (OGN) | APPROX | HLX11 Clinical Trial Phase III Results Announcement | source | |
Organon & Co. (OGN) | APPROX | source |